Creatinine Clearance Calculator (Cockcroft-Gault Equation)

About

The Cockcroft-Gault equation was introduced in 1976 by Donald W. Cockcroft and M. Henry Gault in a landmark paper published in Nephron. They derived the equation from a study of 249 hospitalized Canadian men aged 18-92 years, comparing 24-hour measured creatinine clearance against multiple demographic and biochemical variables. The original equation was developed exclusively in men; the 0.85 correction factor for women was added later based on the observation that females have approximately 15% lower creatinine production due to lower muscle mass. Cockcroft-Gault estimates creatinine clearance (CrCl), which approximates the glomerular filtration rate but exceeds it by approximately 10-20% because creatinine is both filtered and actively secreted by the proximal tubules. Despite the development of more accurate GFR estimating equations such as CKD-EPI, Cockcroft-Gault remains the standard equation for renal drug dose adjustment in clinical practice and in drug development. The United States Food and Drug Administration (FDA) explicitly recommends CrCl calculated by Cockcroft-Gault for pharmacokinetic studies of renally eliminated drugs, and most drug prescribing information specifies dose adjustment thresholds based on CrCl ranges (e.g., ≥60, 30-59, 15-29, <15 mL/min). The equation incorporates body weight, which makes it particularly suitable for individualizing drug doses, unlike eGFR which is normalized to a standard body surface area of 1.73 m². However, this weight dependence creates challenges in obese patients — the equation may overestimate CrCl when using actual body weight in patients with BMI >30. Adjusted or ideal body weight is often recommended in such cases. The equation has been validated across multiple populations, though it tends to overestimate measured CrCl in elderly, malnourished, or edematous patients and underestimate it in young, muscular individuals.

Formula

CrCl = ((140 - Age) × Weight) / (72 × SCr) × (0.85 if female)

The Cockcroft-Gault equation is: CrCl = [(140 - Age) × Weight] / (72 × SCr) × (0.85 if female). All components contribute independently to the result. The term (140 - Age) reflects the physiological decline in renal function with aging — at age 20 this term equals 120, while at age 80 it drops to 60, producing a halving of CrCl from aging alone, all else being equal. Weight in kilograms is multiplied directly, meaning that a heavier patient with identical age and creatinine will have a higher estimated CrCl. This weight dependence is physiologically reasonable — larger individuals have greater muscle mass and higher creatinine generation, requiring higher clearance for the same serum creatinine. However, this also means that obesity artificially inflates CrCl estimates, while cachexia deflates them. The divisor (72 × SCr) incorporates a constant (72) and serum creatinine. The constant 72 was empirically derived from Cockcroft and Gault original dataset and reflects average creatinine production and metabolism in their study population. Serum creatinine appears in the denominator — as creatinine doubles, CrCl halves (assuming other factors constant). This inverse relationship is the core principle of all creatinine-based renal function estimates. The sex correction factor of 0.85 accounts for approximately 15% lower creatinine production in women due to lower average muscle mass. This factor is applied after the main calculation, affecting only the final result. The result is expressed in mL/min as an absolute value — not normalized to body surface area. This is in contrast to eGFR equations (CKD-EPI, MDRD) which report in mL/min/1.73m². A typical normal CrCl for a young adult male is approximately 120 mL/min, and for a young adult female approximately 100 mL/min. CrCl exceeds true GFR because creatinine undergoes tubular secretion, accounting for approximately 10-20% of total renal creatinine elimination. This tubular secretion component can increase in advanced CKD, leading to CrCl overestimating true GFR more significantly. Interpretation of results: CrCl ≥90 mL/min is considered normal, 60-89 mild impairment, 30-59 moderate impairment, 15-29 severe impairment, and <15 kidney failure. These thresholds map directly to drug dosing recommendations in prescribing information.

Score Interpretation

The Cockcroft-Gault equation holds a unique and enduring position in clinical nephrology and pharmacology as the standard tool for renal drug dose adjustment. The FDA Guidance for Industry on Pharmacokinetics in Patients with Impaired Renal Function (2010, updated 2020) explicitly recommends Cockcroft-Gault CrCl for defining renal function categories in clinical trials and for developing dosing recommendations. Consequently, virtually all drug labels approved by the FDA for renally eliminated medications include dose adjustment tables indexed to Cockcroft-Gault CrCl thresholds: ≥90, 60-89, 30-59, 15-29, and <15 mL/min. This creates a regulatory and practical imperative — clinicians must use Cockcroft-Gault to apply the dosing information provided by drug manufacturers. The equation is indispensable across multiple medical specialties. In oncology, CrCl determines dosing for carboplatin (using the Calvert formula), cisplatin, methotrexate, and many others. In infectious disease, it guides dosing of vancomycin, aminoglycosides (gentamicin, tobramycin), fluconazole, acyclovir, and tenofovir. In cardiovascular medicine, it influences enoxaparin dosing for VTE prophylaxis and treatment, and the use of novel oral anticoagulants. In endocrinology, it determines metformin eligibility (contraindicated if CrCl <30). Despite its advantages, Cockcroft-Gault has notable limitations that clinicians must recognize. It was derived from a hospitalized population that differed from today's outpatient populations. It has never been re-expressed for standardized IDMS-calibrated creatinine assays, unlike MDRD and CKD-EPI. The equation also does not account for the well-known phenomenon that tubular secretion of creatinine increases as GFR declines, causing CrCl to progressively overestimate true GFR in advanced CKD. The NKF KDOQI and KDIGO guidelines both acknowledge that eGFR equations are superior for CKD classification, but explicitly recommend CrCl for drug dosing. The choice between Cockcroft-Gault, CKD-EPI, and MDRD for drug dosing remains debated, but Cockcroft-Gault maintains its regulatory status as the reference standard for drug development.

Reference Ranges